<p><sup><i>a</i></sup> Median (inter-quartile range, IQR) for immune measures against vaccine (HPV16, HPV18) and non-vaccine (HPV31, HPV45) genotypes from the Alpha-9 (HPV16, HPV31) and Alpha-7 (HPV18, HPV45) species groups. <i>p</i> value, test for trend for each measure following separation of responses into tertiles (T1-T3) based upon vaccine-type neutralizing antibody responses. N/A, not applicable.</p><p>Comparison of non-vaccine type and vaccine-type immune measures.</p
<p>The five vaccine groups compared with the Control group for immune responses to each vaccine anti...
<p>Incidence comparison between vaccine targeted and non-targeted age groups.</p
Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV1...
<p>Percentage of vaccinees with neutralization titers of ≥20 (left panels) and GMT (right panels) ag...
<p>Percentage of serum samples neutralizing indicated number of A9 (top panel) or A7 (bottom panel) ...
<p>Comparison of the different vaccination strategies in terms of their capacity to induce neutraliz...
<p>Ig anti-PA levels from blood draws between day -1 and 65 were analyzed by repeated measures ANOVA...
<p>Neutralization responses for each vaccinee category were grouped according to blood draw days. Ca...
<p>Box (median and IQR) and whisker (10<sup>th</sup> - 90<sup>th</sup> percentiles) plots of the mag...
<p>Comparison of the HPV vaccinated and non-vaccinated groups by demographic characteristics, STI/HI...
<p>N = Number of subjects in the indicated group who received at least 1 dose of the qHPV vaccine.</...
<p>*Statistically significant differences (p<i> = </i>0.004; Fisher's exact test).</p
<div><p>Background</p><p>Human papillomavirus (HPV) vaccines confer protection against the oncogenic...
<p>9vHPV category included nine vaccine types (6, 11, 16, 18, 31, 33, 45, 52, and 58). ‘9vHPV’ varia...
Comparisons of the vaccine types after the COVID-19 vaccine among sera of participants groups accord...
<p>The five vaccine groups compared with the Control group for immune responses to each vaccine anti...
<p>Incidence comparison between vaccine targeted and non-targeted age groups.</p
Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV1...
<p>Percentage of vaccinees with neutralization titers of ≥20 (left panels) and GMT (right panels) ag...
<p>Percentage of serum samples neutralizing indicated number of A9 (top panel) or A7 (bottom panel) ...
<p>Comparison of the different vaccination strategies in terms of their capacity to induce neutraliz...
<p>Ig anti-PA levels from blood draws between day -1 and 65 were analyzed by repeated measures ANOVA...
<p>Neutralization responses for each vaccinee category were grouped according to blood draw days. Ca...
<p>Box (median and IQR) and whisker (10<sup>th</sup> - 90<sup>th</sup> percentiles) plots of the mag...
<p>Comparison of the HPV vaccinated and non-vaccinated groups by demographic characteristics, STI/HI...
<p>N = Number of subjects in the indicated group who received at least 1 dose of the qHPV vaccine.</...
<p>*Statistically significant differences (p<i> = </i>0.004; Fisher's exact test).</p
<div><p>Background</p><p>Human papillomavirus (HPV) vaccines confer protection against the oncogenic...
<p>9vHPV category included nine vaccine types (6, 11, 16, 18, 31, 33, 45, 52, and 58). ‘9vHPV’ varia...
Comparisons of the vaccine types after the COVID-19 vaccine among sera of participants groups accord...
<p>The five vaccine groups compared with the Control group for immune responses to each vaccine anti...
<p>Incidence comparison between vaccine targeted and non-targeted age groups.</p
Human papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV1...